Remove Healthcare Remove Pharma Remove Transportation
article thumbnail

The financial toxicity of treating cancer

World of DTC Marketing

transportation), and indirect expenses (e.g., Pharma companies are aware that insurers will rarely say no to new cancer therapies, but increased scrutinization of early approvals is on the horizon. copayments and deductibles), nonmedical fees (e.g., lost work and income). The post The financial toxicity of treating cancer.

Insurance 273
article thumbnail

The Caregiver Vertical: How Pharma Engages

Pharma Marketing Network

With an estimated 65 million people serving as caregivers, 1 the role is now a factor in an ever-increasing list of healthcare priorities. If caregiving is positioned as an essential service and caregivers are counted among healthcare’s front-line service providers, 4 does it follow caregivers are a viable healthcare vertical?

Pharma 98
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bridging the healthcare digital divide: a gradual approach to adopting ePI

European Pharmaceutical Review

They are vital to ensuring the safe and effective use of medicines, making them an integral part of healthcare in Europe. 3 Moreover, digital platforms can be tailored to the needs of patients and healthcare professionals, offering accessible, trustworthy and up-to-date information on medicines precisely when required.

article thumbnail

U.S. market access landscape: A push for control is erasing the boundary between payers and providers in U.S. healthcare

Clarivate

healthcare payers and providers are consolidating at a dizzying clip as they seek to gain market share, increase access to care and secure clinical control to improve health outcomes. Payers are responding by creating, acquiring or fortifying provider networks and healthcare clinics of their own.

article thumbnail

How one pharma “family business” places patients first

pharmaphorum

When people think about pharma, they often think about “big” pharma: large, faceless corporations. Every pharma company developing treatments for new diseases is contributing to some degree to better global health. But Giacomo Chiesi, head of Chiesi Global Rare Diseases, thinks of his 6,000-person company as a family business.

article thumbnail

Eli Lilly to help fund cold chain initiative

European Pharmaceutical Review

Cold chain – a vital part of medical logistics Cold chain refers to the transportation and storage of temperature-controlled medications. This is an effort which aims to improve access and address barriers to quality healthcare for 30 million people living in limited-resource settings annually, by 2030.

article thumbnail

OSD contract manufacturing market valued at $54.7 billion by 2030

European Pharmaceutical Review

Tablets were noted to be the most common form of OSD in 2021 because of their convenience and simplicity in production, transportation and delivery to the end user. During 2020, the COVID-19 pandemic depleted the healthcare sector’s revenue due to shortages in the workforce and major disturbance to the raw material supply chain.